Moving -0.50% from the most recent open, shares of AnaptysBio, Inc. (:ANAB) have landed on investor watchlists as the latest bid puts the equity at $49.63.
Investors may be trying to decide which way the stock market will shift over the next couple of quarters. Having a general idea based on research is one thing, but constantly trying to time the market may lead to negative portfolio performance. Of course, overall market downturns can be frustrating to everyone invested in shares. Being able to ride out the day to day volatility and make proper investing decisions based on solid stock examination, may help the investor secure profits down the line. Investors who spend too much time focusing on stocks that have already made a run may find themselves in a sticky situation if they get into the name to late. Just because a certain stock has been going up for a long time, it doesn’t mean that the momentum will be sustained into the future. Taking the time to find quality stocks instead of just looking at the hot stock of the day, may allow investors to keep thriving in the market.

Let’s take a quick look at how the price of AnaptysBio, Inc. (:ANAB) is currently trading in comparison to some of its simple moving averages. At current levels, shares have been seen trading -5.34% away from the 20-day moving average. The stock has been recently separated from the 50-day moving average by -12.86%. Using a broader approach, the stock has been trading -26.51% off of the 200-day moving average. After the latest check-in, shares are -35.78% off of the 50 day high and 7.82% away from the 50 day low number.

In terms of performance, shares of AnaptysBio, Inc. (:ANAB) are -22.87% since the start of 2016. Over the past week, shares are -3.53%. Moving out to look at the previous month performance, the stock is at -7.17%. For the quarter, performance is at -30.63%. During the past six months, AnaptysBio, Inc. (:ANAB)’s stock has been -28.02% and -40.45% for the last 12 months.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Investors may be wondering what’s in store for the next couple of months in terms of the stock market. Bull markets are times when investors may be willing to take some liberties with stock picks. Risk management is typically on the minds of many investors. Investors trying to gain an advantage may be searching for the perfect balance and diversification to help ease the risk and give the portfolio a needed boost. With so many different stocks to study, it may take a while to hone in on the proper ones. Investors will also be closely following the next round of economic data. Investors may be on the lookout for the next major data announcement that either keeps the bulls in charge or ushers in the bears.   

Some investors will scour the markets looking for cheap, quality stocks. These stocks can be attractive for investors looking to find a bargain that could turn into a big winner. Investors may be cautious when searching for these types of stocks. Often times, a stock will see a huge jump and then everyone will hop on the bandwagon to buy without checking into the fundamentals. Sometimes this strategy may work out, but in many cases, the stock has already made the run and become too expensive to add to the portfolio. Conducting diligent research and constantly adding to the individual’s overall market education level may help the investor sift through the sea of stocks and find those names that are really worth getting into.

Analyst Views

Wall Street brokerage firms that regularly cover the stock have provided price targets and recommendations on AnaptysBio, Inc. (:ANAB). According to First Call, the consensus price target for the company is $109.10. The consensus recommendation provided by analysts is currently 2.00. This number is based on a scale from 1 to 5. Analysts rating the company a 1 or 2 indicate a Buy recommendation. Analysts rating the company a 4 or 5 indicate a Sell recommendation. Analysts rating the company a 3 indicate a Hold recommendation.